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Seasonal malaria chemoprevention in the Sahel subregion of 
Africa: a cost-effectiveness and cost-savings analysis
Colin Gilmartin*, Justice Nonvignon*, Matthew Cairns, Paul Milligan, Fadima Bocoum, Peter Winskill, Diego Moroso, David Collins*
Summary
Background The intermittent administration of seasonal malaria chemoprevention (SMC) is recommended to prevent 
malaria among children aged 3–59 months in areas of the Sahel subregion in Africa. However, the cost-effectiveness 
and cost savings of SMC have not previously been evaluated in large-scale studies.
Methods We did a cost-effectiveness and cost-savings analysis of a large-scale, multi-country SMC campaign 
with sulfadoxine–pyrimethamine plus amodiaquine for children younger than 5 years in seven countries in 
the Sahel subregion (Burkina Faso, Chad, Guinea, Mali, Niger, Nigeria, and The Gambia) in 2016. The financial and 
economic costs were analysed from the programmatic perspective and are reported in 2016 US$ for each country. 
The estimated numbers of averted malaria cases, deaths, and disability-adjusted life-years (DALYs) were based on 
numbers of SMC treatments administered and modelled malaria transmission. Cost savings were calculated from 
a programmatic perspective corresponding to the diagnostic and treatment costs for malaria cases averted.
Findings The total cost of SMC for all seven countries was $22·8 million, and the weighted average economic cost of 
administering four monthly SMC cycles was $3·63 per child (ranging from $2·71 in Niger to $8·20 in The Gambia). 
Based on 80% modelled effectiveness of SMC, the incremental economic cost per malaria case averted ranged from 
$2·91 in Niger to $30·73 in The Gambia; the cost per severe case averted ranged from $119·63 in Niger to $506·00 in 
The Gambia; the cost per death averted ranged from $533·56 in Niger to $2256·92 in The Gambia; and the cost per 
DALY averted (discounted by 3%) ranged from $18·66 in Niger to $78·91 in The Gambia. The estimated total 
economic cost savings to the health systems in all seven countries were US$66·0 million and the total net economic 
cost savings were US$43·2 million.
Interpretation SMC is a low-cost and highly cost-effective intervention that contributes to substantial cost savings by 
reducing malaria diagnostic and treatment costs among children.
Funding Unitaid.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
In sub-Saharan Africa, almost 70% (292 000 of 429 000) of 
malaria deaths in 2015 occurred in children younger 
than 5 years.1 In the Sahel, where the majority of 
childhood malarial disease and deaths occur during 
and immediately after the short rainy season, WHO 
recommends the intermittent administration of seasonal 
malaria chemoprevention (SMC) with sulfadoxine–
pyrimethamine plus amodiaquine to prevent Plasmodium 
falciparum malaria among children aged 3–59 months.2 
The objective of SMC is to maintain therapeutic 
antimalarial medicine concentrations in the blood 
throughout the period of greatest malarial risk.2 If given 
to populations at risk, SMC could avert several million 
malaria cases and tens of thousands of childhood deaths 
due to malaria annually.3 Despite this evidence, as of 2015, 
SMC had been administered largely through small-scale 
(ie, subnational) or pilot projects, with ten countries 
adopting SMC as a national policy.1
Recognising the potential health impact of large-
scale SMC distribution, in 2014, Unitaid launched the 
Achieving Catalytic Expansion of Seasonal Malaria 
Chemoprevention in the Sahel (ACCESS-SMC) project, 
which supported SMC administration in 2015 and 
2016 in seven countries in the Sahel: Burkina Faso, 
Chad, Guinea, Mali, Niger, Nigeria, and The Gambia. 
ACCESS-SMC promoted the widespread adoption of 
SMC by showing its feasibility and impact on a large 
scale and creating the demand for, and the supply of, 
SMC medicine. In collaboration with National Malaria 
Control and Elimination Programs, ACCESS-SMC 
provided nearly 12·5 million monthly SMC cycles in 
2015 and 25·1 million in 2016.
Although studies have shown the safety,4 potential 
effectiveness,3 and cost-effectiveness5–7 of SMC using 
sulfadoxine–pyrimethamine plus amodiaquine, no cost-
effectiveness studies of large-scale or multi-country 
programmes have been done, nor any cost-savings 
analyses of SMC. The aim of this study was to evaluate the 
cost-effectiveness of SMC in seven countries in the Sahel, 
in terms of its cost per averted malaria case, per averted 
severe malaria case, per averted death, and per averted 
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disability-adjusted life-year (DALY). The cost savings due 
to SMC were also estimated from the programmatic 
perspective, related to the diagnosis and treatment costs 
that would have been incurred in the absence of SMC.
Methods
Study design
The analysis comprises two main components: a cost-
effectiveness analysis of the incremental costs and effects 
of SMC from a programmatic perspective, and a cost-
savings analysis to estimate the treatment and diagnostic 
costs saved based on malaria cases averted. The cost-
effectiveness analysis component provides only a partial 
view of the intervention’s benefits because it did not 
account for net savings. The reporting of results followed 
the Consolidated Health Economic Evaluation Reporting 
Standards checklist (appendix pp 3–6).
Intervention
This study was done after the SMC campaign (July 
to December, 2016) and the time horizon of the 
analysis was 1 year (2016). SMC was administered in 
once monthly cycles for 4 months, with the timing 
depending on the malaria transmission patterns in each 
country (table 1). Each monthly cycle lasted 3–5 days, 
depending on the expected number of children that 
SMC distributors could reach in their catchment areas 
(appendix pp 7–10).
Each cycle, the first sulfadoxine–pyrimethamine plus 
amodiaquine dose was provided to eligible children by 
trained distributors on day 1 and the remaining two doses 
of amodiaquine were provided by the children’s caregivers 
on days 2 and 3. The method of SMC distribution was a 
mixture of door-to-door, fixed-point, and mobile-point 
distribution, depending on the country and context. In 
2016, 47 238 trained distributors, comprising both unpaid 
volunteers and salaried health centre personnel, 
administered SMC.
The number of monthly SMC treatments given to 
children younger than 5 years was estimated from 
ACCESS-SMC distribution records, adjusted to account 
for some treatments given to older children. The 
percentage of treatments that were administered to 
children aged 5 years or older was estimated based on 
the population age structure in each country according 
to UN World Population Prospects projections8 and 
estimates obtained from coverage surveys.9 In total, 
25·1 million monthly SMC cycles were administered, 
of which an estimated 21·9 million were given to 
children younger than 5 years (table 1).
Cost analysis
Using an ingredients-based approach, the study 
estimated the economic cost of the intervention in 
2016, comprising the recurrent financial costs incur-
red (for non-govern mental organisations [NGOs] 
Research in context
Evidence before this study
We searched PubMed, Cochrane Library, Malaria in Pregnancy 
Library, African Journals Online, Cumulative Index to Nursing 
and Allied Health Literature, and Google Scholar for studies on 
seasonal malaria chemoprevention (SMC) and intermittent 
preventive treatment and their costs, cost-effectiveness, cost 
savings, and cost barriers. The search was limited to English 
language articles published from Jan 1, 2007, to May 31, 2017. 
The keywords ”malaria OR falciparum” were combined with 
the following search terms: “economics”, “cost”, “cost 
sharing”, “cost effectiveness”, “cost allocation”, “cost control”, 
“cost of illness”, “health care costs”, “provider costs”, “societal 
costs”, “intermittent preventive treatment”, “sulfadoxine”, 
“sulphadoxine”, and “pyrimethamine”. Our search identified 
20 studies, of which 15 reported costs associated with SMC or 
intermittent preventive treatment. Eight studies reported 
financial and economic costs; however, three did not 
present financial costs and four did not present economic 
costs. This previous research indicated that the administration 
of SMC to children in the Sahel subregion of Africa could avert 
millions of cases of Plasmodium falciparum malaria and 
thousands of deaths per year. However, to our knowledge, 
no studies have evaluated the cost-effectiveness or 
corresponding cost savings for large-scale distribution of SMC 
(ie, beyond small-scale subnational or pilot projects within 
countries in the region). 
Added value of this study
This study provides timely and important evidence on the cost, 
cost-effectiveness, and potential cost savings of the first large-
scale, multi-country SMC campaign. The study shows that SMC, 
when distributed on a large scale, is a cost-effective approach to 
reducing the burden of malaria in children younger than 5 years 
in the Sahel and can result in large cost savings when 
accounting for malaria cases averted.
Implications of all the available evidence
The findings of this study will help country health systems and 
technical and financial partners to evaluate and prioritise 
investments in malaria and advance global efforts for malaria 
control and prevention. The continued implementation and 
expansion of SMC in eligible areas in and outside of the Sahel 
subregion could help to reduce the burden of malaria, which 
remains one of the leading causes of morbidity and mortality 
among young children globally. By reducing malaria cases and 
deaths, as well as associated costs for diagnosis and treatment, 
SMC could also contribute to substantial cost savings incurred 
by national health systems. 
See Online for appendix
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and govern ments) and the opportunity costs of 
labour by non-salaried volunteer distributors (appendix 
pp 11–14). The analyses were done using Microsoft 
Excel 2016. Costs were not discounted because they 
were incurred within the 1-year time horizon of the 
intervention.
Costs were calculated separately for each country 
and were a mixture of actual and normative costs. 
Programmatic data on the numbers and types of SMC 
distributors and supervisors were provided by in-
country partners. Financial costs were obtained from 
accounting and budget records of implementing NGO 
partners and through interviews with personnel 
involved in programme management, supervision, and 
distribution. Normative data on the time spent by 
Ministry of Health (MOH) supervisors and managers 
were collected through interviews in each country. The 
costs of MOH labour were based on the average total 
time spent supporting the campaign multiplied by the 
average hourly wage (assuming 8 h of work per day), 
which was based on the average monthly gross income 
(from all sources, including salary). Per diem payments 
were considered a financial cost.
The opportunity cost of volunteer, non-salaried 
distributors was calculated based on interviews and 
considered the number of hours spent on distribution, 
training, and other activities during each monthly cycle. 
These costs were estimated by multiplying the total 
number of hours spent during the campaign by the 
income they would have received for other productive 
activities (based on the national daily average minimum 
wage in each country). Costs were estimated in 
2016 US$. If local currency was used, costs were 
converted using 2016 exchange rates, with $1 equal to 
591 XOF, 591 XAF, 8347 GNF, 260 NGN, or 43 GMD. 
Sources for currency rates and national average wages 
used for this analysis can be found in the appendix 
(pp 11–14).
Burkina Faso Chad Guinea Mali Niger Nigeria The Gambia
Programme overview
Months of SMC distribution July to October August to December July to October July to October August to October August to November July to October
Days per monthly SMC cycle 4 3 4 5 5 4 5
Geographical coverage 31 districts in six regions 14 districts in 
four regions
Eight districts in 
four regions
20 districts in 
five regions
11 districts in four 
regions
34 local government 
areas in two states
18 districts in 
two regions
Distribution approach Door-to-door and fixed-
point at health centres







Number of distributors 13 957 8029 2234 5318 3809 13 309 582
SMC coverage
Monthly SMC cycles 
administered (all ages)
5 780 062 2 511 371 1 750 224 4 667 224 3 810 088 6 301 058 297 453
Monthly SMC cycles 
administered (<5 years)*
4 479 548 2 297 904 1 473 689 4 125 826 3 470 990 5 746 565 290 314
SMC distributed per monthly cycle (all ages)
Cycle 1 1 325 487 615 671 439 796 1 060 268 915 334 967 009† 74 666
Cycle 2 1 437 420 652 539 416 822 1 126 460 978 011 1 763 595 75 741
Cycle 3 1 488 996 712 192 449 513 1 197 464 969 810 1 765 074 73 955
Cycle 4 1 528 159 530 969† 444 093 1 283 032 946 933 1 805 380 73 091
Number of cycles of SMC received by children‡, % 
None 0·7% 8·5% 3·3% 8·6% 7·9% 17·3% 16·6%
One cycle 0·7% 24·0% 3·2% 5·0% 5·2% 19·2% 6·4%
Two cycles 2·3% 27·0% 11·0% 9·6% 14·4% 20·5% 11·6%
Three cycles 5·1% 28·1% 9·5% 19·9% 22·3% 23·4% 21·7%
Four cycles 91·2% 12·4% 73·0% 56·9% 50·2% 19·5% 43·7%
Monthly SMC cycles by distribution approach (all ages), n (%)
Door to door 5 682 031 (98·3%) 2 511 371 (100%) 1 750 224 (100%) 0 207 023 (5·4%) 0 297 453 (100%)
Fixed point 98 031 (1·7%) 0 0 982 128 (21·0%) 0 0 0
Mobile point 0 0 0 3 685 096 (79·0%) 0 0 0
Mixed methods 0 0 0 0 3 603 065 (94·6%) 6 301 058 (100%) 0
SMC=seasonal malaria chemoprevention. *The percentage of SMC treatments going to children younger than 5 years was estimated based on data from the ACCESS-SMC coverage surveys and UN country-
specific estimates of the percentage of children in each age group. †In Nigeria and Chad, SMC medicine shortages contributed to low coverage in the first cycle in Nigeria and the fourth cycle in Chad, and fewer 
children were reached compared with other cycles. ‡Coverage estimates are survey-weighted estimates from surveys in 13 063 children (874 in Burkina Faso, 1010 in Chad, 1743 in Guinea, 799 in Mali, 5646 in 
Niger, 1853 in Nigeria, and 1138 in The Gambia).
Table 1: SMC programme overview and coverage in the Sahel subregion of Africa in 2016
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Predicting malaria cases, deaths, and DALYs averted 
by SMC
Modelled predictions of malaria cases in the absence 
of SMC were estimated using a combination of 
methods. A mathematical model of malaria transmission 
estimated the incidence of malaria, severe malaria, and 
malaria deaths at the level of the first administrative 
subdivision in each country.10 The administrative sub-
divisions were calibrated to estimates of the prevalence 
of P falciparum from the Malaria Atlas Project and 
incorporated expected effects of long-lasting insecticidal 
nets based on 2015 coverage. The predicted incidence 
was adjusted by a scale factor based on clinical trials in 
Burkina Faso and Mali in 2016,9 with model predictions 
for the same locations. For Chad, Niger, and northwest 
Nigeria, available prevalence data were scarce and out of 
date; therefore, the analysis used adjusted estimates, 
relying on prevalence data obtained from surveys in 
ACCESS-SMC areas at the end of the 2015 transmission 
season, and assuming a linear relationship between 
incidence and prevalence. To capture uncertainty in the 
incidence, a range of plausible values was calculated 
(appendix pp 15–29). For the sensitivity analysis, we 
assumed that the uncertainty in the mean incidence in 
each country could be as much as half of the difference 
between the smallest and largest country estimate. 
Therefore, a range was obtained by calculating the 
central estimate for each country plus or minus a quarter 
of the overall range.
The number of malaria cases that would have occurred 
in the counterfactual scenario, in which children did not 
receive SMC, was estimated by multiplying the monthly 
malaria incidence by the number of children younger 
than 5 years who were treated in that month. Estimates 
of the number of malaria cases averted by SMC in 
each month were then obtained by multiplying the 
estimated total number of malaria cases in the counter-
factual scenario by 0·20 or 0·15 (ie, assuming modelled 
effectiveness of 80% or 85% in the month SMC is 
administered, respectively, with no effect outside this 
time period). The effective ness of SMC in the 28 days 
after treatment was estimated as 88% (95% CI 79–94) in 
a series of case-control studies.11 The results presented 
in this analysis are for 80% SMC effectiveness and 
use lower-bound estimates of malaria incidence in 
each country, therefore representing a conservative 
estimate of SMC effectiveness. Additional details on 
the lower-bound and upper-bound estimates for 80% 
and 85% effective ness are provided in the appendix 
(pp 15–29). The same logic and the same assumptions 
regarding malaria incidence and SMC effectiveness 
were used to estimate the severe malaria cases averted 
by SMC.
The number of deaths averted was estimated from the 
number of severe cases averted, assuming a constant case 
fatality rate among severe cases, and also scaling by a factor 
to account for the fact that not all severe cases present to a 
health facility. DALYs averted were derived as a product of 
the total estimated number of deaths averted and DALYs 
per death. The estimate of 28·6 discounted (at 3%) DALYs 
and 65·4 undiscounted DALYs per death (average age of 
2 years) was derived from a randomised controlled trial on 
home management of fever among children in Ghana.12 
We also estimated DALYs without age weighting.
Cost-effectiveness analysis
SMC was considered an additional intervention to existing 
health interventions already being delivered in each 
country. Incremental cost-effectiveness ratios (ICERs) 
were calculated by dividing the total economic cost of the 
SMC intervention in each country by the corresponding 
effectiveness estimates for children younger than 5 years. 
ICERs are presented with and without discounting of 
DALYs. The cost per child treated with the recommended 
four monthly cycles of SMC was estimated by dividing the 
total economic cost by the equivalent number of children 
younger than 5 years who received four doses in each 
country. The equivalent number of children was calculated 
by dividing the total number of monthly cycles in the 
under-5 age group by four monthly cycles.
Cost-effectiveness thresholds, according to WHO-
CHOICE standards,13 were used to determine the cost-
effectiveness of SMC relative to each country’s 2016 gross 
domestic product (GDP) per capita (according to World 
Bank data). Based on this approach, an intervention (per 
DALY averted) that costs less than three-times the 
country’s GDP per capita is considered cost-effective, 
and an intervention that costs less than the GDP per 
capita is considered highly cost-effective. We present the 
ICERs under two scenarios: scenario one includes effects 
in children younger than 5 years and total costs of the 
intervention (which include costs to older children, given 
that in reality some older children received SMC), and 
scenario two includes the apportioned costs and effects 
for only children younger than 5 years (appendix pp 29–32).
Cost-savings analysis
Cost savings of SMC were estimated from a programmatic 
perspective. Malaria diagnosis and treatment costs were 
based on a review by White and colleagues14 of cost 
studies done in several countries in Asia and Africa and 
figures were inflated to 2016 US$ using the inflation rate 
of 11·0% for the years 2009 to 2016. Because these figures 
included costs from Asia and South Africa, which were 
generally higher than the costs in other sub-Saharan 
African countries, the analysis used only the first quartile 
medians for calculating cost savings and therefore may 
be conservative. The first quartile median economic diag-
nosis and treatment costs were $8·86 for uncomplicated 
malaria cases and $28·03 for severe malaria cases, 
with severe malaria treatment costs being incurred at 
the hospital inpatient level. These unit costs were then 
multiplied by the numbers of malaria cases and severe 
malaria cases averted in each country to estimate the 
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total costs saved. It was assumed that severe malaria 
cases would have been initially treated as uncomplicated 
cases before receiving recommended treatment. It was 
assumed that 60% of malaria cases in children younger 
than 5 years would be diagnosed and treated at a health 
facility.15 Net economic savings were calculated by 
subtracting the cost of the intervention from the expected 
cost savings in each country.
Sensitivity analysis
One-way sensitivity analyses were done to test the 
robustness of the ICERs by varying key cost and 
effective ness estimates that had some degree of 
uncertainty. These included using undiscounted and 
discounted (3%) DALYs, MOH management costs 
(–50% to +20%) and the monthly protective effectiveness 
of SMC (70% to 90%). MOH management costs were 
reduced by 50% in the low scenario, based on 
widespread consensus among the authors that these 
estimates were overstated by MOH officials, and 
increased by 20% in the high scenario. The sensitivity 
analysis also considered the effect of changes in the 
percentage of malaria cases in children younger than 
5 years that would be diagnosed and treated at a health 
facility (30% to 70%; appendix pp 33–37).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. CG, JN, and DC had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
Among the seven countries, the total number of SMC 
doses administered ranged from 297 453 in The Gambia 
to 6·3 million in Nigeria. The majority of SMC doses 
administered reached the intended target population of 
children younger than 5 years. SMC administration 
methods varied among countries but the most common 
were door-to-door and mixed-method approaches. The 
total recurrent economic cost for all ages was 
$22·8 million, comprising $20·6 million in financial 
costs and $2·2 million in volunteer opportunity costs 
(table 2). SMC drugs and supplies represented the 
highest financial cost in every country, followed by the 
per diem and travel payments made to the distributors, 
except in The Gambia, where NGO programme manage-
ment costs were the second-highest costs. The weighted 
average economic cost of administering four monthly 
SMC cycles was $3·63 per child, ranging from $2·71 per 
child in Niger to $8·20 per child in The Gambia (table 3). 
The high cost of SMC in The Gambia was due to the 
relatively small population of children covered by the 
intervention and the relatively high total recurrent costs. 
The Gambia was the only country that recorded SMC 
coverage using Android mobile phones, which required 
training and remunerating of data recorders, many of 
whom were recruited from outside of the intervention 
areas. Compared with other countries, The Gambia had 
Burkina Faso Chad Guinea Mali Niger Nigeria The Gambia Total
Non-governmental financial costs 4 216 563 1 755 718 1 386 686 3 123 431 2 143 028 4 476 871 581 387 17 683 684
SMC drugs and supplies 1 789 281 726 130 526 260 1 432 512 1 199 903 1 888 603 117 070 7 679 759
Meetings 161 301 179 520 36 754 123 227 8241 127 822 3840 640 706
Distributor per diem and travel 1 133 563 407 563 214 124 449 915 386 701 800 446 108 053 3 500 365
Direct supervisor per diem and travel 277 786 153 330 13 728 150 305 75 973 385 917 11 691 1 068 729
Other supervisor per diem and travel 154 025 72 060 108 838 236 898 92 957 171 296 68 457 904 529
Training 273 756 34 320 149 930 143 404 92 674 428 728 49 881 1 172 692
NGO programme management 215 088 39 364 138 311 305 918 130 650 388 547 116 280 1 334 158
Social mobilisation and behaviour 
change communication
144 607 113 367 112 038 230 844 68 405 148 060 97 437 914 759
Other costs 67 157 30 063 86 702 50 408 87 525 137 452 8680 467 987
Governmental financial costs 666 767 201 565 90 906 564 542 242 633 1 121 188 12 865 2 900 464
Distributor salaries 107 622 0 0 405 229 0 235 878 0 748 729
Supervisor salaries 138 136 96 336 39 325 120 270 87 114 490 967 4745 976 893
Programme management salaries 421,009 105 229 51 581 39 042 155 519 394 343 8120 1 174 843
Total financial costs 4 883 330 1 957 282 1 477 592 3 687 973 2 385 661 5 598 059 594 252 20 584 149
Volunteer opportunity costs 581 274 465 637 80 030 139 390 192 791 723 402 15 637 2 198 161
Volunteer distributors 581 274 414 185 80 030 139 390 179 843 637 248 15 637 2 047 607
Volunteer supervisors 0 51 452 0 0 12 948 86 154 0 150 555
Total costs 5 464 604 2 422 920 1 557 622 3 827 362 2 578 453 6 321 460 609 889 22 782 310
All costs are in 2016 US$. Costs in other currencies were converted, with $1 equal to 591 XOF, 591 XAF, 8347 GNF, 260 NGN, or 43 GMD. SMC=seasonal malaria 
chemoprevention. NGO=non-governmental organisation.
Table 2: Recurrent economic costs of SMC intervention by resource type and funding source
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higher associated SMC medicine costs for customs, 
clearance, warehousing, and distribution. The total cost 
of providing four monthly SMC cycles via door-to-door 
distribution ranged from $3·56 per child in Guinea 
to $4·05 per child in Niger, with The Gambia being 
an outlier at $8·20 per child. In the two countries 
where separate cost data were available for fixed-point 
distribution, the cost of administering four monthly 
SMC cycles was $4·73 per child in Mali, where this 
represented the major delivery strategy, and $12·22 per 
child in Burkina Faso, where this comprised less than 
2% of treatments.
Among children younger than 5 years, SMC was 
estimated to have had a substantial effect on malaria 
morbidity and mortality in ACCESS-SMC areas. Based 
on the assumed 80% SMC monthly protective effective-
ness rate, the intervention averted between 4·9 million 
and 7·1 million malaria cases, between 130 297 and 
158 683 severe malaria cases, between 29 214 and 
35 579 deaths, and between 835 512 and 1·02 million 
DALYs (3% discounted) in 2016 (table 4). Estimates for 
85% SMC monthly effectiveness showed greater effects 
(table 4).
The cost per malaria case averted ranged from $2·91 in 
Niger to $30·73 in The Gambia (table 4). The cost per 
severe malaria case averted ranged from $119·63 in 
Niger to $506·00 in The Gambia. The cost per death 
averted ranged from $533·56 in Niger to $2256·92 in 
The Gambia. The cost per DALY averted (discounted) 
ranged from $18·66 in Niger to $78·91 in The Gambia. 
ICERs with undiscounted DALYs are also presented in 
table 4. In all countries, the cost per DALY averted (both 
discounted and undiscounted) was highly cost-effective.
The estimated recurrent economic costs saved were 
$66·0 million for all seven countries and ranged from 
$291 966 in The Gambia to $20·1 million in Nigeria 
(table 5). After deducting the costs of administering 
SMC, the net economic cost savings were $43·2 million, 
which greatly exceeded the economic costs of adminis-
tering SMC in every country, with the exception of 
The Gambia. In Mali, for example, the economic cost of 
diagnosis and treatment saved of $14·5 million was more 
than four-times the economic costs of administering 
SMC of $3·8 million.
The sensitivity analyses are presented in the appendix 
(pp 33–37). Tornado diagrams for each country show the 
variation in ICERs (cost per DALY averted) around the 
base-case analysis. The low and high values used for 
sensitivity analyses reflect possible values for each 
parameter. Although all parameters affected the ICER, 
under all scenarios the ICER remained highly cost-
effective in the seven countries. The cost per DALY 
Burkina Faso Chad Guinea Mali Niger Nigeria The Gambia
Non-governmental financial costs 2·92 2·80 3·17 2·68 2·25 2·84 7·82
SMC drugs and supplies 1·24 1·16 1·20 1·23 1·26 1·20 1·57
Meetings 0·11 0·29 0·08 0·11 0·01 0·08 0·05
Distributor per diem and travel 0·78 0·65 0·49 0·39 0·41 0·51 1·45
Direct supervisor per diem and travel 0·19 0·24 0·03 0·13 0·08 0·24 0·16
Other supervisor per diem and travel 0·11 0·11 0·25 0·20 0·10 0·11 0·92
Training 0·19 0·05 0·34 0·12 0·10 0·27 0·67
NGO programme management 0·15 0·06 0·32 0·26 0·14 0·25 1·56
Social mobilisation and behaviour change communication 0·10 0·18 0·26 0·20 0·07 0·09 1·31
Other costs 0·05 0·05 0·20 0·04 0·09 0·09 0·12
Governmental financial costs 0·46 0·32 0·21 0·48 0·25 0·71 0·17
Distributor salaries 0·07 0·00 0·00 0·35 0·00 0·15 0·00
Supervisor salaries 0·10 0·15 0·09 0·10 0·09 0·31 0·06
Programme management salaries 0·29 0·17 0·12 0·03 0·16 0·25 0·11
Total financial costs 3·38 3·12 3·38 3·16 2·50 3·55 7·99
Volunteer opportunity costs 0·40 0·74 0·18 0·12 0·20 0·46 0·21
Volunteer distributors 0·40 0·66 0·18 0·12 0·19 0·40 0·21
Volunteer supervisors 0·00 0·08 0·00 0·00 0·01 0·05 0·00
Total costs 3·78 3·86 3·56 3·28 2·71 4·01 8·20
Cost per child by distribution approach
Door to door 3·64 3·86 3·56 ·· 4·05 ·· 8·20
Fixed point 12·22 ·· ·· 4·73 ·· ·· ··
Mobile point ·· ·· ·· 2·89 ·· ·· ··
Mixed methods ·· ·· ·· ·· 2·63 4·01 ··
All costs are in 2016 US$. SMC=seasonal malaria chemoprevention. NGO=non-governmental organisation.
Table 3: Recurrent economic costs per child for treatment with four doses of SMC
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averted (both discounted and undiscounted) was highly 
cost-effective. Changes in MOH management costs had 
little effect on the ICER due to the small financial 
contribution of governments towards the intervention 
relative to donor contributions. Although changes to 
SMC protective effectiveness had little effect on the 
ICER, this one-way sensitivity analysis does highlight 
the potential for SMC to become less effective in the 
future for a number of reasons, including the 
development of resistance.
The sensitivity analysis also considered the effect of 
changes in care-seeking for children younger than 5 years 
with malaria. In the main analysis, we assumed that 60% 
of these children would be diagnosed and treated at a 
health facility (based on Tiono and colleagues15). However, 
in the sensitivity analysis (appendix p 37), a low value of 
30% and a high value of 70% were considered. Under 
the low scenario, the net economic cost savings 
were $10·2 million, which exceeded the economic 
costs of administering SMC with the exception of Chad 
and The Gambia. In the high scenario, net savings 
were $54·2 million, which exceeded the cost of SMC 
administration, with the exception of The Gambia.
Discussion
This large-scale, multi-country study found SMC to be a 
low-cost and highly cost-effective intervention that 
contributes to substantial cost savings by reducing 
malaria diagnostic and treatment costs among children. 
The economic costs of one monthly dose ($0·68 to $2·05) 
and four cycles of SMC ($2·71 to $8·20 per child) are 
within the range of previous analyses. A 2016 study in 
Ghana by Nonvignon and colleagues6 reported a cost (in 
2015) of $22·53 per fully dosed child aged three to 
59 months ($5·63 per monthly dose) in one region. A 
2017 study by Pitt and colleagues7 estimated a unit cost 
(in 2010) of between $0·38 and $2·74 per child aged up 
to 10 years with one monthly dose of SMC. The cost per 
malaria case averted ranged from $2·91 to $30·73, 
which is lower than the $107 reported by Nonvignon 
Burkina Faso Chad Guinea Mali Niger Nigeria The Gambia Total
Total economic costs of administering SMC 5 464 604 2 422 920 1 557 622 3 827 362 2 578 453 6 321 460 609 889 22 782 310
Diagnosis and treatment economic costs 
saved
12 310 252 3 288 511 3 755 813 14 469 046 11 767 661 20 071 640 291 966 65 954 888
Net economic costs saved 6 845 648 865 591 2 198 191 10 641 683 9 189 209 13 750 180 –317 923 43 172 578
All costs are in 2016 US$. Cost savings are calculated assuming 80% effectiveness of SMC and lower incidence estimates. SMC=seasonal malaria chemoprevention.
Table 5: Estimated cost savings for children younger than 5 years
 Burkina Faso Chad Guinea Mali Niger Nigeria The Gambia Total*
SMC effectiveness (80% effectiveness, lower incidence estimates)
Malaria cases averted 913 043 236 182 283 659 1 086 056 886 767 1 514 044 19 846 4 939 596
Severe malaria cases averted 27 092 9640 6682 27 832 21 554 36 291 1205 130 297
Deaths averted 6074 2161 1498 6240 4833 8137 270 29 214
DALYs averted (3% discounting) 173 727 61 815 42 846 178 473 138 210 232 712 7729 835 512
DALYs averted (no discounting) 397 263 141 353 97 977 408 116 316 047 532 146 17 673 1 910 576
SMC effectiveness (85% effectiveness, lower incidence estimates)
Malaria cases averted 970 109 250 943 301 387 1 153 935 942 189 1 608 672 21 086 5 248 321
Severe malaria cases averted 28 786 10 243 7100 29 572 22 901 38 559 1281 138 441
Deaths averted 6454 2296 1592 6630 5135 8645 287 31 040
DALYs averted (3% discounting) 184 585 65 678 45 524 189 627 146 848 247 257 8212 887 731
DALYs averted (no discounting) 422 092 150 188 104 101 433 624 335 800 565 405 18 778 2 029 987
ICERs for children <5 years (80% effectiveness, lower incidence estimates)
Cost per malaria case averted 5·99 10·26 5·49 3·52 2·91 4·18 30·73 ··
Cost per severe malaria case averted 201·70 251·34 233·11 137·51 119·63 174·19 506·00 ··
Cost per death averted 899·62 1121·01 1039·72 613·33 533·56 776·90 2256·92 ··
Cost per DALY averted (3% discounting) 31·46† 39·20† 36·35† 21·45† 18·66† 27·16† 78·91† ··
Cost per DALY averted (no discounting) 13·76† 17·14† 15·90† 9·38† 8·16† 11·88† 34·51† ··
2016 GDP per capita 627 664 662 780 364 2176 473 ··
ICER=incremental cost-effectiveness ratio. SMC=seasonal malaria chemoprevention. DALY=disability-adjusted life-year. GDP=gross domestic product. *Data for individual countries might not add to totals due 
to rounding. †These values were considered highly cost-effective (defined as the cost per DALY averted being less than the 2016 GDP per capita).
Table 4: Effectiveness and ICERs of SMC for children younger than 5 years
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and colleagues.6 The cost per malaria death averted in 
our study ($533·56 to $2256·92) was lower in all seven 
countries compared with the equivalent figure of $3298, 
reported by Nonvignon and colleagues for Ghana, which 
was based on 80% monthly protective effectiveness. 
However, the two previous studies had differing 
methods of calculating costs and predic ting effectiveness 
outcomes. Nonvignon and colleagues included capital 
items (eg, vehicles) in cost calculations,6 and Pitt and 
colleagues considered only costs at the district level 
and below.7
To our knowledge, no previous study in sub-Saharan 
Africa has reported a cost per DALY averted for SMC. 
However, the results are also within the range of other 
malaria interventions. The median ICER per DALY 
averted was $27 (range $8·15 to $110) for insecticide-
treated bednets, $143 ($135 to $150) for indoor residual 
spraying, and $24 ($1·08 to $44·24) for intermittent 
preventive treatment.14 Based on our study, SMC is overall 
highly cost-effective in averting DALYs among children in 
areas of highly seasonal malaria transmission. However, 
with the increasing reduction of malaria-related mortality 
globally, economic analyses should focus more on malaria 
cases and DALYs than on deaths to inform decision 
making.6,16
Interventions such as SMC, insecticide-treated 
bednets, and intermittent preventive treatment should 
also be appraised for their level of affordability, especially 
given the push for more stringent cost-effectiveness 
thresholds.17 The SMC intervention analysed in this 
study was funded by Unitaid in these seven countries, 
with relatively small financial contributions from 
governments. In the absence of future donor funding 
for SMC, governments might be unable to sustain the 
attained levels of SMC coverage and reduction in 
malaria burden.
The overall cost-effectiveness of SMC would probably 
be improved by greater intervention coverage (ie, treating 
more children and ensuring a higher proportion receive 
the full course), as evidenced by the coverage survey 
data. In The Gambia, the relatively high fixed costs of 
implementation and the small population of children 
covered with SMC contributed to a high ICER. SMC 
medicine shortages contributed to low coverage in the 
first cycle in Nigeria and the fourth cycle in Chad. 
Nevertheless, in the absence of major funding from 
Unitaid, the levels of SMC coverage and corresponding 
cost-effectiveness of the intervention might have been 
different.
Although the study presents the costs of different 
SMC approaches (eg, door-to-door or fixed-point 
distribution), these were considered complimentary in 
countries which utilised multiple distribution methods, 
with each having their own benefits. Door-to-door 
distribution probably provides better access to the 
medication for people from lower socioeconomic 
quintiles and those living in hard-to-reach areas than 
other distribution methods. Although reaching rural 
areas might be more expensive and less cost-effective, 
these populations might receive the most benefit from 
the intervention, given issues of access to quality 
malaria diagnosis and treatment services. Fixed-point 
distribution at a health facility provides an opportunity 
for children to be screened by a health provider and 
receive other preventive services (eg, immunisations). 
Because health facility personnel are remunerated 
regardless of whether they provide SMC, the 
intervention might not necessarily be con sidered an 
additional cost but rather an opportunity cost, because it 
reduces the time that they have available to provide 
other services. Nevertheless, reductions in malaria 
incidence due to SMC probably would reduce the time 
required for diagnosing and treating cases, thereby 
freeing up their time for other activities.
This study further shows that SMC can produce 
substantial savings in terms of averted diagnosis and 
treatment costs when compared with routine care. These 
estimates assume the same unit financial and economic 
costs for treating uncomplicated and severe malaria in 
all seven countries. Depending on the proportion of 
malaria cases treated at a health facility, these estimates 
could represent an overestimation or underestimation 
of the actual cost savings. Nevertheless, the cost of SMC 
implementation in most countries does not represent 
an added cost, but rather an investment that could result 
in savings to the health system. The total cost saving 
for diagnosis and treatment in 2016 was estimated to 
be $66·0 million in the seven countries and the net 
economic cost savings were $43·2 million after 
deducting the costs of administration ($22·8 million). 
These savings could free up much-needed resources to 
expand SMC to the estimated 13·6 million children 
living in eligible geographical areas, of which more than 
9 million live in Nigeria.18
However, the study did have a number of limitations. 
We excluded the costs of several key programmatic 
components, such as some capital costs (eg, NGO and 
MOH office buildings and vehicles) and start-up costs, the 
majority of which were incurred in previous years. Start-
up costs (accounting for 4·39% of total costs) comprised 
time and resources for the preparation of reporting 
tools and training materials, stakeholder meetings, and 
the development of behaviour-change communication 
messaging (eg, radio and print advertising). The cost of 
pharmacovigilance systems for drug safety monitoring, 
coverage surveys, and monitoring of drug resistance was 
also excluded.
Moreover, the study was done from the programmatic 
perspective and did not measure the economic costs 
experienced by children and families accessing SMC (eg, 
the value of time taken to access care and out-of-pocket 
costs) nor the associated costs for treating children with 
secondary effects, although cases were reportedly low.11 
We expect that families would experience considerable 
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savings related to costs averted for accessing and paying 
out of pocket for malaria diagnosis and treatment, 
especially in countries which have user fees in place. 
Although the study obtained time allocation estimates 
(eg, from SMC distributors) through interviews, direct 
observation would have been preferable, but it was not 
possible due to the timing of data collection.
In addition, as indicated in the methods, the study 
presents the cost per child based on the equivalent 
number of children who received four doses in each 
country. However, this does not represent the true cost of 
a fully adherent child, as evidenced by the coverage 
survey data on the percentage of children who received 
the recommended four monthly doses of SMC in each 
country.
Although there is uncertainty around the modelled 
predictions of malaria incidence, conservative estimates 
were used to avoid overestimating the impact of SMC. 
Health management information system data indicate 
substantial reductions in malaria cases at health 
facilities since the introduction of SMC;9 however, these 
data do not provide reliable estimates of numbers of 
cases averted, due to the large proportion of people with 
malaria that do not present to health facilities.
The cost-effectiveness of integrating SMC with other 
services could not be determined due to the absence of 
reliable data. In Burkina Faso, Mali, and Niger, SMC 
was reportedly integrated with the provision of rapid 
diagnostic tests for malaria, malaria treatment, malnu-
trition screening, and referrals. Because SMC is one 
of the few platforms that reaches vulnerable children 
younger than 5 years simultaneously on a large scale, 
further research could help to identify opportunities for 
integration19 and improve its cost-effectiveness.5
In conclusion, this study is the first to estimate the 
cost-effectiveness and cost savings of a large scale, multi-
country SMC campaign targeting children younger than 
5 years in the Sahel region of sub-Saharan Africa. Our 
results show that SMC is both cost-effective and cost 
saving in the seven countries evaluated.
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